Trilogy Capital’s AB InBev BUD Stock Holding History

Trilogy Capital’s Portfolio BUD Stock Details BUD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-75	Closed	-$7K	–	193
2018 Q3	$7K	Buy	75 +54	+257%	+$5.26K	﹤0.01%	350
2018 Q2	$2K	Hold	21	–	–	﹤0.01%	449
2018 Q1	$2K	Buy	+21	New	+$2.33K	﹤0.01%	376

Other funds holding BUD

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HMP

HS Management Partners New York $286M AUM 2.97% 1-Year Est. Return

Trilogy Capital's BUD Position: Q4 2018 in Review

Trilogy Capital sold out of AB InBev (BUD) in Q4 2018, closing a stake of 75 shares — an estimated $7K sold.

Trilogy Capital first reported a position in BUD in Q1 2018 and held it in 3 quarters. The position peaked at $7K in Q3 2018. 513 funds tracked by Wall St. Rank hold BUD as of Q4 2018.

Trilogy Capital reported no remaining AB InBev position as of Q4 2018 after selling out during the quarter.
Trilogy Capital sold 75 AB InBev shares in Q4 2018, an estimated $7K.
Trilogy Capital first reported a position in AB InBev in Q1 2018 and held it in 3 quarters.
Trilogy Capital's AB InBev position peaked at $7K in Q3 2018.
513 funds tracked by Wall St. Rank held AB InBev as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.